Lv6
2140 积分 2023-12-05 加入
系列问答150——什么是细胞因子释放综合征？
9天前
已完结
Risk-directed management of chronic kidney disease
15天前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
1个月前
已完结
Inebilizumab for Treatment of IgG4-Related Disease
1个月前
已完结
FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases
1个月前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
2个月前
已完结
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
2个月前
已完结
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
2个月前
已完结
2019年美国血浆置换学会血浆置换和免疫吸附临床实践指南(第8版)解读
2个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2个月前
已完结
皖公网安备34019202002308
